Economic evaluations of exome and genome sequencing in pediatric genetics: considerations towards a consensus strategy

References

• Ayme S, Schmidtke J. Networking for rare diseases: a necessity for Europe. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2007;50(12):1477–1483.
   PubMed Web of Science ®Google Scholar
• Zurynski Y, Frith K, Leonard H, et al. Rare childhood diseases: How should we respond? Arch Dis Child. 2008;93(12):1071–1074.
   PubMed Web of Science ®Google Scholar
• Bick D, Dimmock D. Whole exome and whole genome sequencing. Curr Opin Pediatr. 2011;23(6):594–600.
   PubMed Web of Science ®Google Scholar
• Vrijenhoek T, Kraaijeveld K, Elferink M, et al. Next-generation sequencing-based genome diagnostics across clinical genetics centers: Implementation choices and their effects. Eur J Hum Genet. 2015;23(9):1142–1150.
   PubMed Web of Science ®Google Scholar
• Koboldt DC, Steinberg KM, Larson DE, et al. The next-generation sequencing revolution and its impact on genomics. Cell. 2013;155(1):27–38.
   PubMed Web of Science ®Google Scholar
• Alam K, Schofield D. Economic evaluation of genomic sequencing in the paediatric population: a critical review. Eur J Hum Genet. 2018;26(9):1241–1247.
   PubMed Web of Science ®Google Scholar
• Buchanan J, Wordsworth S, Schuh A. Issues surrounding the health economic evaluation of genomic technologies. Pharmacogenomics. 2013;14(15):1833–1847.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE) [Internet] Guide to the methods of technology appraisal 2013. [cited 2021 Feb 25]. Available from: https://www.nice.org.uk/process/pmg9/resources/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781.
   Google Scholar
• Schwarze K, Buchanan J, Taylor JC, et al. Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature. Genet Med. 2018;20(10):1122–1130.
   PubMed Web of Science ®Google Scholar
• Drummond MF, Sculpher MJ, Claxton K, et al. Methods of economic evaluation in healthcare programmes. 4th ed. Oxford: Oxford University Press; 2015.
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, The PRISMA Group, et al. Preferred reporting items for systematic reviews and Meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
   PubMed Web of Science ®Google Scholar
• Soden SE, Saunders CJ, Willig LK, et al. Effectiveness of exome and genome sequencing guided by acuity of illness for diagnosis of neurodevelopmental disorders. Sci Transl Med. 2014;6(265):265ra168.
   PubMed Web of Science ®Google Scholar
• van Nimwegen KJ, Schieving JH, Willemsen MA, et al. The diagnostic pathway in complex paediatric neurology: a cost analysis. Eur J Paediatr Neurol. 2015;19(2):233–239.
   PubMed Web of Science ®Google Scholar
• Valencia CA, Husami A, Holle J, et al. Clinical impact and cost-effectiveness of whole exome sequencing as a diagnostic tool: a pediatric center’s experience. Front Pediatr. 2015;3:67.
   PubMed Web of Science ®Google Scholar
• Joshi C, Kolbe DL, Mansilla MA, et al. Reducing the cost of the diagnostic odyssey in early onset epileptic encephalopathies. Biomed Res Int. Epub. 2016;2016:1–8.
   Web of Science ®Google Scholar
• Sabatini LM, Mathews C, Ptak D, et al. Genomic sequencing procedure microcosting analysis and health economic cost-impact analysis: a report of the association for molecular pathology. J Mol Diagn. 2016;18(3):319–328.
   PubMed Web of Science ®Google Scholar
• Nolan D, Carlson M. Whole exome sequencing in pediatric neurology patients: Clinical implications and estimated cost analysis. J Child Neurol. 2016;31(7):887–894.
   PubMed Web of Science ®Google Scholar
• Monroe GR, Frederix GW, Savelberg SM, et al. Effectiveness of whole-exome sequencing and costs of the traditional diagnostic trajectory in children with intellectual disability. Genet Med. 2016;18(9):949–956.
   PubMed Web of Science ®Google Scholar
• Schofield D, Alam K, Douglas L, et al. Cost-effectiveness of massively parallel sequencing for diagnosis of paediatric muscle diseases. NPJ Genom Med. 2017;2:4.
   PubMed Web of Science ®Google Scholar
• Vissers L, van Nimwegen KJM, Schieving JH, et al. A clinical utility study of exome sequencing versus conventional genetic testing in pediatric neurology. Genet Med. 2017;19(9):1055–1063.
   PubMed Web of Science ®Google Scholar
• Hayeems RZ, Bhawra J, Tsiplova K, et al. Care and cost consequences of pediatric whole genome sequencing compared to chromosome microarray. Eur J Hum Genet. 2017;25(12):1303–1312.
   PubMed Web of Science ®Google Scholar
• Stark Z, Schofield D, Alam K, et al. Prospective comparison of the cost-effectiveness of clinical whole-exome sequencing with that of usual care overwhelmingly supports early use and reimbursement. Genet Med. 2017;19(8):867–874.
   PubMed Web of Science ®Google Scholar
• Tan TY, Dillon OJ, Stark Z, et al. Diagnostic impact and cost-effectiveness of whole-exome sequencing for ambulant children with suspected monogenic conditions. JAMA Pediatr. 2017;171(9):855–862.
   PubMed Web of Science ®Google Scholar
• Tsiplova K, Zur RM, Marshall CR, et al. A microcosting and cost-consequence analysis of clinical genomic testing strategies in autism spectrum disorder. Genet Med. 2017;19(11):1268–1275.
   PubMed Web of Science ®Google Scholar
• Dillon OJ, Lunke S, Stark Z, et al. Exome sequencing has higher diagnostic yield compared to simulated disease-specific panels in children with suspected monogenic disorders. Eur J Hum Genet. 2018;26(5):644–651.
   PubMed Web of Science ®Google Scholar
• Yuen T, Carter MT, Szatmari P, et al. Cost-effectiveness of genome and exome sequencing in children diagnosed with autism spectrum disorder. Appl Health Econ Health Policy. 2018;16(4):481–493.
   PubMed Web of Science ®Google Scholar
• Stark Z, Schofield D, Martyn M, et al. Does genomic sequencing early in the diagnostic trajectory make a difference? A follow-up study of clinical outcomes and cost-effectiveness. Genet Med. 2019;21(1):173–180. Corrected and republished from: Genet Med. 2019;21(2):516.
   PubMed Web of Science ®Google Scholar
• Howell KB, Eggers S, Dalziel K, et al. A population-based cost-effectiveness study of early genetic testing in severe epilepsies of infancy. Epilepsia. 2018;59(6):1177–1187.
   PubMed Web of Science ®Google Scholar
• Vrijenhoek T, Middelburg EM, Monroe GR, et al. Whole-exome sequencing in intellectual disability; cost before and after a diagnosis. Eur J Hum Genet. 2018;26(11):1566–1571.
   PubMed Web of Science ®Google Scholar
• Stark Z, Lunke S, Brett GR, et al. Meeting the challenges of implementing rapid genomic testing in acute pediatric care. Genet Med. 2018;20(12):1554–1563.
   PubMed Web of Science ®Google Scholar
• Palmer EE, Schofield D, Shrestha R, et al. Integrating exome sequencing into a diagnostic pathway for epileptic encephalopathy: evidence of clinical utility and cost effectiveness. Mol Genet Genomic Med. 2018;6(2):186–199.
   PubMed Web of Science ®Google Scholar
• Demos M, Guella I, DeGuzman C, et al. Diagnostic yield and treatment impact of targeted exome sequencing in early-onset epilepsy. Front Neurol. 2019;10:434.
   PubMed Web of Science ®Google Scholar
• Radio FC, Ruzzeddu M, Bartuli A, et al. Cost-effectiveness of exome sequencing: an Italian pilot study on undiagnosed patients. New Genet Soc. 2019;38(3):249–263.
   Web of Science ®Google Scholar
• Schofield D, Rynehart L, Shresthra R, et al. Long-term economic impacts of exome sequencing for suspected monogenic disorders: diagnosis, management, and reproductive outcomes. Genet Med. 2019;21(11):2586–2593.
   PubMed Web of Science ®Google Scholar
• Yokoi TA, Enomoto Y, Tsurusaki Y, et al. An efficient genetic test flow for multiple congenital anomalies and intellectual disability. Pediatr Int. 2020;62(5):556–561.
   PubMed Web of Science ®Google Scholar
• Dragojlovic N, van Karnebeek CDM, Ghani A, et al. The cost trajectory of the diagnostic care pathway for children with suspected genetic disorders. Genet Med. 2020;22(2):292–300.
   PubMed Web of Science ®Google Scholar
• Kosaki R, Kubota M, Uehara T, et al. Consecutive medical exome analysis at a tertiary center: diagnostic and health-economic outcomes. Am J Med Genet A. 2020;182(7):1601–1607.
   PubMed Web of Science ®Google Scholar
• Smith HS, Swint JM, Lalani SR, et al. Exome sequencing compared with standard genetic tests for critically ill infants with suspected genetic conditions. Genet Med. 2020;22(8):1303–1310.
   PubMed Web of Science ®Google Scholar
• Yeung A, Tan NB, Tan TY, et al. A cost-effectiveness analysis of genomic sequencing in a prospective versus historical cohort of complex pediatric patients. Genet Med. 2020;22(12):1986–1993.
   PubMed Web of Science ®Google Scholar
• Drummond M, Brixner D, Gold M, et al. Toward a consensus on the QALY. Value Health. 2009;12(Suppl 1):S31–S35.
   PubMed Web of Science ®Google Scholar
• Global Economics and Evaluation of Clinical Genomics Sequencing Working Group (GEECS) [Internet, cited 2021 Mar 15]. Available from: https://www.geecsecon.org/.
   Google Scholar